Recarbrio for injection, for intravenous use
Merck
Recarbrio is a pharmaceutical agent that treats infections caused by susceptible gram-negative microorganisms in patients 18 years of age or older.
It is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor and relebactam, a betalactamase inhibitor, which treats hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, complicated urinary tract infections and complicated intra-abdominal infections.
Common side effects include diarrhea, nausea, headache, vomiting, increased alanine aminotransferase, increased aspartate aminotransferase, infusion site reaction, fever and high blood pressure.
Next >>
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tell Us What You Think!
You must be logged in to post a comment.